Moreover, the fact that tamoxifen, which is the estrogen receptor antagonist approved by the Food and Drug Administration FDA, reduces breast cancer risk provides a basis for the breast cancer risk-enhancing role of estrogen [38]. This evidence concerns the gene ESR1 and breast carcinoma.